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Cardiovascular growth must balance stabilizing
signals required to maintain endothelial connections
and network integrity with destabilizing signals
that enable individual endothelial cells to migrate
and proliferate. The cerebral cavernous malforma-
tion (CCM) signaling pathway utilizes the adaptor
protein CCM2 to strengthen endothelial cell junctions
and stabilize vessels. Here we identify a CCM2
paralog, CCM2L, that is expressed selectively in
endothelial cells during periods of active cardiovas-
cular growth. CCM2L competitively blocks CCM2-
mediated stabilizing signals biochemically, in
cultured endothelial cells, and in developing mice.
Loss of CCM2L reduces endocardial growth factor
expression and impairs tumor growth and wound
healing. Our studies identify CCM2L as a molecular
mechanism by which endothelial cells coordinately
regulate vessel stability and growth during cardio-
vascular development, as well as postnatal vessel
growth.
INTRODUCTION
The heart and blood vessels mediate gas exchange and deliver
nutrients, signalingmolecules, and circulating cells to the tissues
of the body. The vertebrate cardiovascular system is lined by
specialized endothelial cells that direct its growth and function.
During cardiovascular development the heart and vessels are
first formed by endothelial cells that arise from mesodermal
precursors through a process of cardiogenesis and vasculogen-
esis (Potente et al., 2011; Risau, 1997). After de novo formation
of the heart and earliest embryonic vessels, vascular growth
occurs through angiogenic sprouting of endothelial cells from
preexisting vessels (Potente et al., 2011).342 Developmental Cell 23, 342–355, August 14, 2012 ª2012 ElsevieIn the functioning cardiovascular system, endothelial cells
must be tightly connected to each other through cell-cell junc-
tions to maintain a closed vascular network through which blood
can circulate (Dejana et al., 2009). In contrast, during angiogen-
esis endothelial cells must transiently disconnect from each
other and the existing network in order to proliferate andmigrate.
Endothelial cell junctions and vessel stability must therefore be
molecularly regulated during vascular growth in a highly spatially
and temporally coordinated manner to allow growth without
compromising the integrity of the existing cardiovascular
network. Vascular endothelial growth factor (VEGF), a protein
that both loosens endothelial junctions and stimulates endothe-
lial proliferation (Murohara et al., 1998; Senger et al., 1983), is one
such regulator. However, because tumor vessels are able to
overcome the effects of VEGF blockade, other molecular mech-
anisms of regulating vessel stability and vessel growth must
exist, and their identification is critical to design more effective
therapies.
The cerebral cavernous malformation (CCM) signaling
pathway has recently been identified as a critical positive regu-
lator of endothelial junctions and vessel stability. The CCM
pathway consists of three adaptor proteins, KRIT1 (aka
CCM1), CCM2, and PDCD10 (aka CCM3) that were identified
as disease genes in patients with cerebral vascular malforma-
tions. The CCM proteins bind each other (Voss et al., 2007)
and the HEG receptor (Kleaveland et al., 2009). Human CCMs
exhibit defective endothelial junctions (Clatterbuck et al.,
2001), and loss of HEG, CCM1, CCM2, or CCM3 function results
in abnormal endothelial cell junctions and vascular lumen forma-
tion in mice and zebrafish in vivo and endothelial cells in vitro
(Glading et al., 2007; Kleaveland et al., 2009; Stockton et al.,
2010;Whitehead et al., 2009; Zheng et al., 2010). Genetic studies
in mice and fish have also demonstrated that the CCM signaling
pathway plays an essential and conserved role in cardiovascular
development. Mice and fish lacking CCM1 or CCM2 fail to
develop lumenized branchial arch arteries that connect the heart
to the aorta (Whitehead et al., 2004, 2009; Zheng et al., 2010),
and loss of HEG in both species confers defects in heart growth
(Kleaveland et al., 2009; Mably et al., 2003, 2006). Wer Inc.
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regulated to permit efficient angiogenesis and cardiogenesis.
To test this hypothesis we searched for novel regulators of
angiogenesis that might function through the CCM pathway.
We demonstrate that a paralog of CCM2 (CCM2L) opposes the
stabilizing effects of CCM signaling to liberate angiogenic endo-
thelial cells during cardiovascular growth. Biochemical studies
and genetic analysis of mice lacking HEG, CCM2, and/or
CCM2L reveal that CCM2L functions by competing with CCM2
for binding to the HEG-CCM1 complex and uncoupling these
upstream components of the pathway from CCM3, a critical
stability effector, while activating expression of factors that
support cardiovascular growth. Loss of CCM2L prevents tumor
growth in mice and delays wound healing, findings consistent
with a specific role in regulating angiogenesis in vivo. Ccm2LGFP
reporter mice reveal that CCM2L expression in vivo is detected
only in endothelial cells, especially those that participate in active
cardiovascular growth. We propose that CCM2L functions as
a molecular mechanism through which CCM signaling converts
endothelial cells from a stable to an angiogenic phenotype and
by which endothelial responses in vascular disease and growth
may be specifically targeted.
RESULTS
Identification of a CCM2 Paralog that Binds CCM1
and HEG but Not CCM3
To identify potential novel regulators of the CCM signaling
pathway, we used BLAST searching of the EST and Ensemble
databases to identify genes encoding structurally related pro-
teins.Agene that encodes aprotein predicted tobehighly homol-
ogous toCCM2 thatwedesignatedCCM2L (akaBC020535 in the
mouse and C20orf160 in the human) was identified in the human,
mouse, and zebrafish databases (Figure 1A; Figure S1 available
online). The best-characterized domain of the CCM2 protein is
the phosphotyrosine binding (PTB) domain that mediates inter-
action with CCM1 (Zawistowski et al., 2005). Ccm2L encodes
a PTB domain that contains a long insertion between the b6
and b7 sheets but is highly homologous to that of CCM2 in the
b5 strand through which DAB1-like PTB domains are believed
to interact with peptide ligands (Figure 1A; Stolt et al., 2003; Uhlik
et al., 2005), suggesting that CCM2L may also bind CCM1.
Biochemical studies have demonstrated that CCM2 binds
CCM1 via its PTB domain, and CCM3 through an as yet unde-
fined region of the protein, to nucleate a signaling complex that
is recruited to the HEG receptor by CCM1 (Kleaveland et al.,
2009; Voss et al., 2009; Zawistowski et al., 2005; Zheng et al.,
2010). To determine if CCM2L proteins are also able to complex
with CCM1 and CCM3, epitope-tagged CCM2 and CCM2L
proteins were coexpressed with CCM1 and/or CCM3 in
HEK293T cells and coimmunoprecipitation experiments were
performed. CCM1 coimmunoprecipitated efficiently with both
CCM2 and CCM2L (Figure 1B). In contrast, CCM3 coimmuno-
precipitated with CCM2 and not with CCM2L (Figure 1C).
Studies of CCM2 binding to CCM1 have identified two PTB
domain point mutants, L198R and F217A, that disrupt binding
to CCM1 (Zawistowski et al., 2005). To further investigate the
mechanism by which CCM2L binds CCM1, we next tested
whether the equivalent CCM2L PTB domain point mutants,DevelopL306R and F325A (see Figure 1A for comparison to mouse
sequence in which L198 is M198), are capable of binding
CCM1. The L306R point mutant that is equivalent to a CCM
disease-associated mutation in CCM2 (Denier et al., 2004), but
not the F325A mutant, conferred severe loss of CCM1 binding
by CCM2L (Figure 1D). Thus, CCM2L binds CCM1 via its PTB
domain in a manner that is similar but not identical to that of
CCM2. Previous studies have demonstrated that the CCM
protein complex associates highly efficiently with the HEG
receptor intracellular tail (HEG-IC) via CCM1 (Kleaveland et al.,
2009; Zheng et al., 2010). Beads coupled to the intracellular
(IC) tail of HEG but not integrin aIIb efficiently pulled down
a complex of ccm1, ccm2, and ccm3 when those proteins
were coexpressed in HEK293T cells (Figure 1E). In contrast,
when ccm1, ccm2L, and ccm3 proteins were coexpressed,
HEG-IC beads pulled down a complex containing only ccm1
and ccm2L (Figure 1E). These findings indicate that both
CCM2 and CCM2L interact with CCM1 and HEG via their PTB
domains but that ccm2L does not associate with ccm3, a critical
downstream effector of the known CCM signaling pathway.
CCM2L Competes with CCM2 for CCM1 Binding
The finding that CCM2L binds CCM1 suggested that CCM2 and
CCM2L may compete for CCM1 binding. Because endothelial
CCM1 and CCM2 levels were too low to detect endogenous
protein interaction in cultured endothelial cells and anti-CCM2L
antibodies are not yet available to determine if CCM2L and
CCM2 compete for binding to CCM1, we compared the ability
of known amounts of FLAG-taggedCCM2orCCM2L to compete
with HA-tagged CCM2 (Figure 1F) or CCM2L (Figure 1G) for
binding to CCM1. The addition of FLAG-CCM2L or FLAG-
CCM2 resulted in a dramatic reduction in the amount of CCM1
associated with HA-CCM2 (Figure 1F). Conversely, the addition
of FLAG-CCM2or FLAG-CCM2L resulted in adramatic reduction
in the amount of CCM1 associated with HA-CCM2L (Figure 1G).
Finally, addition of CCM2L L306R, a PTB point mutant with
severely reduced CCM1 binding (Figure 1C), failed to competi-
tively block CCM2 binding to CCM1 (Figure 1H). These studies
demonstrate that CCM2 and CCM2L compete for binding to
CCM1 and that the expression of CCM2L may thereby prevent
HEG-CCM1 complexes from associating with CCM3.
Ccm2L Expression Is Spatially Restricted to Endothelial
Cells and Temporally Linked to Cardiovascular Growth
Although an essential function for CCM2 has been demonstrated
in endothelial cells using genetic approaches (Boulday et al.,
2009; Whitehead et al., 2009), endothelial Ccm2 levels are too
low to be detected above background using either LacZ or
GFP knockin reporter alleles or radioactive in situ hybridization
(Kleaveland et al., 2009; Whitehead et al., 2009). Northern blot
analysis of adult mouse tissues revealed Ccm2L mRNA expres-
sion in adult heart and lung, organs with large endothelial cell
populations (Figure S1). To better define the expression pattern
of Ccm2L, we performed in situ hybridization studies using
mouse embryos from E9.5 to E18. Ccm2L mRNA was detected
exclusively along the endothelial cell border of the developing
heart and vessels (Figures 2A–2E).Ccm2L expressionwas stron-
gest in the E10.5 heart but was not detected in the heart or else-
where after E12.5 using in situ hybridization. Consistent withmental Cell 23, 342–355, August 14, 2012 ª2012 Elsevier Inc. 343
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Figure 1. CCM2L Competes with CCM2 for Binding to CCM1 but Does Not Bind CCM3
(A) ClustalW alignment of the predicted PTB domains ofmouse CCM2L, CCM2, and DAB1 are shown. Green shading indicates identity in all three proteins, yellow
shading indicates identity in at least two proteins, and blue shading indicates conserved residues in at least two proteins. Red asterisks indicate CCM2L L306
and F325 amino acid residues. The predicted beta strands and alpha helices are ordered according to those of DAB1 PTB domain.
(B) CCM2L binds CCM1. Flag-CCM2 or Flag-CCM2L was coexpressed with HA-CCM1 in HEK293T cells, and anti-Flag immunoprecipitations (IP) were
performed.
(C) CCM2L does not bind CCM3. HA-ccm2 or HA-ccm2L was coexpressed with Myc-ccm3 in HEK293T cells, and anti-HA immunoprecipitations (IP) were
performed. Red asterisk notes a weak nonspecific detection of the IgG band.
(D) The CCM2L L306R, but not the CCM2L F325A, mutation disrupts CCM2L-CCM1 interaction. Flag-tagged CCM2L, CCM2L-L306R, CCM2L-F325A, or
CCM2L-L306R/F325A was coexpressed with HA-CCM1, and anti-Flag immunoprecipitations (IP) were performed.
(E) The HEG intracellular tail forms a complex with CCM1 and CCM2L that does not include CCM3. HA-ccm2L or HA-ccm2, FLAG-ccm1, and Myc-ccm3 were
expressed in HEK293 cells and pull downs performed with affinity matrices containing the intracellular tail of either the aIIb integrin subunit (aIIb) or the HEG
receptor (HegIC). Total protein expression in pull-down input is shown by immunoblot (IB) analysis (right).
(F–H) CCM2L and CCM2 compete for CCM1 binding. (F) Cell lysates containing the same amount of MYC-CCM1 and HA-CCM2 were mixed
with control lysate or lysate containing FLAG-CCM2L (middle lane) or FLAG-CCM2 (right lane) and HA-CCM2 immunoprecipitated with anti-HA antibodies.
The amounts of immunoprecipitated HA-CCM2 and coimmunoprecipitated MYC-CCM1 are shown above, and the amounts of FLAG-CCM2L and
Developmental Cell
CCM2L Controls Vascular Stability and Growth
344 Developmental Cell 23, 342–355, August 14, 2012 ª2012 Elsevier Inc.
Developmental Cell
CCM2L Controls Vascular Stability and Growththese findings in the mouse, RT-PCR detected CCM2L expres-
sion in primary human microvascular endothelial cells and
primary human lymphatic endothelial cells but not in primary
human keratinocytes (Figure 2F). In contrast to CCM2L and
TIE2, a known endothelial specific gene, CCM1, CCM2, and
CCM3 were detected in equal abundance in primary keratino-
cytes and endothelial cells. Measurement of transcript copy
numbers revealed that CCM2L is expressed at levels similar to
those ofCCM1,CCM2, andCCM3 in endothelial cells (Figure 2F).
These studies suggest that CCM2L is expressed in an endothe-
lial-specific pattern and at a basal level that is similar to those of
CCM1, CCM2, and CCM3.
To further characterizeCcm2L expression and function in vivo,
we used homologous recombination in ES cells to place a cDNA-
encoding nuclear-localized GFP in frame with the start methio-
nine of Ccm2L (Figure S1). GFP was detected exclusively in
the nuclei of PECAM+ endocardial and endothelial cells of
Ccm2LGFP mice (Figures 2G–2T). GFP was not detected in all
endothelial cells but was instead found in a small subset of endo-
thelial cells that varied with embryonic age. Ccm2LGFP was
strongly expressed in the endocardium, where nuclear GFP
was detected by E9.5, peaked at E11.5 (when 20% of endocar-
dial cell nuclei were GFP+), and declined thereafter (Figures
2G–2K). Ccm2LGFP expression was undetectable in myocardial
cells at all time points (Figures 2G–2J). Ccm2LGFP expression
was strongly detected in the endothelial cells of the dorsal aorta
and cardinal vein prior to E12.5 but not at later time points
(Figures 2L–2N). Throughout gestation Ccm2LGFP expression
was detected in a small number of endothelial cells in vessels
scattered throughout the embryo (Figure 2O). These cells were
frequently adjacent to one another within a single vessel and
often found in nonlumenized extensions from lumenized,
blood-containing vessels (Figure 2O), for example, endothelial
cells invading the neural tube at E10.5 (Figures 2P and 2Q),
consistent with a role in active vessel and heart growth.
A site of highly active angiogenesis is the retina, where a
vascular complex forms rapidly during the first weeks of life
(Saint-GeniezandD’Amore, 2004).Consistentwitha role inactive
vessel growth, the endothelial cells of most vessels within the
Ccm2LGFP retina wereGFP+ at P6 (Figures 2S and 2T). However,
the tip cells that lead retinal vascular growth were mostly GFP
(Figure 2T, discussed further below). Despite a spatial associa-
tion between Ccm2LGFP expression and nascent vessels, GFP+
endothelial cells did not exhibit an increase in BrdU uptake
(Figure S1), indicating that expression of Ccm2L does not corre-
late directly with endothelial proliferation. These studies reveal
that Ccm2L expression is highly specific and restricted to endo-
thelial cells of the growing heart and vessels in a pattern con-
sistent with a role in active angiogenesis and cardiogenesis.
Heg and Ccm2L Function in a Pathway Required
for Cardiac Growth
To test the requirement for CCM2L in vivo, we generated
Ccm2L/mice by intercrossing Ccm2LGFP/+ mice. QuantitativeFLAG-CCM2 added are shown below. Note that addition of FLAG-CCM2L or
HA-CCM2 to a similar degree. (G) The level of MYC-CCM1 coimmunoprecipita
was measured as in (F). (H) The level of MYC-CCM1 coimmunoprecipitated w
CCM2L-L306R.
Developreal-time PCR (qPCR) and RT-PCR analysis of Ccm2LGFP/GFP
embryos and tissues revealed that the Ccm2LGFP allele fails to
express any Ccm2L mRNA 30 of exon 1 and (Figure S1) and is
therefore a null allele. Ccm2L/ mice were born in normal
numbers from Ccm2L+/ intercrosses and grew to maturity
without overt phenotypes on mixed SV129J;C57Bl/6, 100%
SV129J, and 100% C57Bl/6 genetic backgrounds (Table S1).
Thus, unlike CCM2, CCM2L is not required for mouse cardiovas-
cular development.
Like Ccm2L, Heg is strongly expressed in endocardial and
endothelial cells (Kleaveland et al., 2009). HEG-deficient mice
exhibit predominantly postnatal cardiovascular phenotypes,
including thinning of the myocardial wall, which can result in
cardiac rupture and death (Kleaveland et al., 2009). In contrast,
CCM1-deficient and CCM2-deficient mouse embryos die
by E9.5 because of defective branchial arch artery lumen forma-
tion and an inability to circulate blood, a defect reproduced
by endothelial-specific loss of CCM2 (Boulday et al., 2009;
Whitehead et al., 2004, 2009). This phenotype is also observed
in Heg/;Ccm2+/ embryos (Kleaveland et al., 2009),
demonstrating that HEG and CCM2 function in a common
pathway and that loss of HEG sensitizes this pathway to partial
loss of CCM2. Because CCM2L associates with HEG
and CCM1, we next generated animals lacking both Heg
and Ccm2L to determine whether and how CCM2L might
interact with the known CCM signaling pathway. Analysis of
116 progeny of Heg+/;Ccm2L+/ intercrosses revealed no
livebornHeg/;Ccm2L/ animals (p < 0.01).Heg/;Ccm2L+/
and Heg+/;Ccm2L/ animals survived to birth, but all
Heg/;Ccm2L/ embryos died prior to E11.5 (Table S2). In
contrast to Ccm2/ and Heg/;Ccm2+/ embryos, however,
Heg/;Ccm2L/ embryos were viable at E9.5, developed
patent branchial arch arteries, and had normal blood circulation
at this time point (Figures 3A–3F and Table S2). By E10.5Heg/;
Ccm2L/ embryos exhibited severe myocardial thinning,
reduced ventricular trabeculation, and dilated atria (Figures
3G–3I). High-frequency ultrasound revealed a marked reduction
in the systolic fractional shortening of the left ventricle in E10.5
Heg/;Ccm2L/ embryos (Figure 3L), confirming that
Heg/;Ccm2L/embryos die of heart failure. Analysis of
BrdU uptake revealed reduced proliferation of myocardial but
not endocardial cells in the hearts of E10.5 Heg/;Ccm2L/
embryos (Figure 3M). Thus, Heg and Ccm2L operate in a
common pathway in vivo that supports cardiac growth, a role
distinct from that of HEG-CCM2 signaling and consistent with
the expression pattern of Ccm2L.
HEG-CCM2L Signaling Regulates Endocardial Growth
Factor Expression
Because HEG and CCM2L physically associate and are ex-
pressed strongly in endocardial cells, the reduced myocardial
proliferation observed inHeg/;Ccm2L/ embryos suggested
that HEG-CCM2L signaling might regulate the endocardial
production of growth factors required to support myocardialFLAG-CCM2 reduce the level of CCM1 that is coimmunoprecipitated with
ted with HA-CCM2L in the presence of either FLAG-CCM2L or FLAG-CCM2
ith HA-CCM2 is reduced in the presence of FLAG-CCM2L but not FLAG-
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Figure 2. Ccm2L Is Expressed in Endothelial Cells that Participate in Active Cardiovascular Growth
(A–E) In situ hybridization reveals endothelial-specific expression of Ccm2L. Shown are sagittal sections of an E11.5 mouse embryo. Ccm2L signal is shown in
pink (arrows) and DAPI staining of cell nuclei in blue. ao, aorta; cv, cardinal vein; a, atrium; v, ventricle.
(F) Quantitative RT-PCR measurement of mRNA transcripts encoding CCM1, CCM2, CCM2L, CCM3, and the endothelial-specific control gene TIE2
in cultured human microvascular endothelial cells from the skin (HMVEC) and heart (HMVEC-C), dermal lymphatic endothelial cells (LEC), and human
primary keratinocytes (HPK) is shown. The black and red arrowheads indicate that no expression of TIE2 or CCM2L was detected in HPKs. n = 4; error bars
indicate SEM.
(G–K) Ccm2LGFP expression in the endocardium. Shown are low (above) and high (below) magnification images of cardiac trabeculae from E10.5–E15.5 hearts
following immunostaining for GFP (green) and the endothelial cell marker PECAM (red). (K) Quantitation ofCcm2LGFP-expressing endocardial cells during mouse
cardiac development. n = 5; error bars indicate SEM.
(L–N) Expression of Ccm2LGFP in the dorsal aorta (da) and cardinal vein (cv) at E10.5.
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CCM2L Controls Vascular Stability and Growthgrowth at this time point (e.g., neuregulin and FGF family
members; Gassmann et al., 1995; Iwamoto et al., 2003; Lavine
et al., 2005; Lu et al., 2010). To test the requirement for HEG-
CCM2L signaling specifically in endothelial cells, we generated
mice carrying a conditional Heg allele using homologous recom-
bination in ES cells (Figure S2). Cre-mediated recombination of
the Hegfl allele results in deletion of exon 1 and creation of
a Heg allele that we have previously shown to be null (Figure S2;
Kleaveland et al., 2009). Analysis of 44 offspring of Tie2-
Cre;Ccm2L/Heg+/ 3 Ccm2L/Hegfl/fl matings revealed no
liveborn Tie2-Cre;Hegfl/;Ccm2L/ animals (p < 0.001). Tie2-
Cre;Hegfl/;Ccm2L/ animals exhibited embryonic lethality
at E11 associated with myocardial thinning, a phenotype
identical to that observed in Heg/;Ccm2L/ animals (Figures
3J and 3K). These findings and the endothelial-specific expres-
sion pattern of Ccm2L indicate that HEG and CCM2L function
in a common endothelial pathway during cardiovascular
development.
To determine if HEG-CCM2L signaling regulates endocardial
growth factor expression, qPCR was performed to measure the
levels of Neuregulin, Fgf9, Fgf12, and Fgf16 in the hearts of
mice lacking CCM2L, HEG, or both HEG and CCM2L. Although
CCM2L-deficient embryos exhibited normal cardiac growth,
significantly reduced levels of Fgf12 and Fgf16 but not Fgf9
or Neuregulin mRNA were detected in E10.5 Ccm2L/ hearts
at this time point (Figure 3N). At E9.5, a time point prior to any
detectable cardiac phenotype, when compared to Heg+/;
Ccm2L+/ littermates Heg/;Ccm2L+/, Heg+/;Ccm2L/,
and Heg/;Ccm2L/ hearts exhibited a graded loss of
expression of Fgf16, a gene required to stimulate myocardial
growth at this time point (Lavine et al., 2005; Lu et al., 2008)
(Figure 3O). Consistent with these loss-of-function findings
in vivo, adenoviral overexpression of CCM2L in endothelial cells
in vitro conferred an increase in FGF12 and FGF16 expression
(Figure 3P). These studies demonstrate that HEG-CCM2L
signaling regulates the expression of myocardial growth factors
by endothelial cells in the E9.5–E10.5 heart and explain
why combined deficiency of HEG and CCM2L is lethal at this
time point.
Ccm2L and Ccm2 Play Opposing Roles during
Cardiovascular Development
The studies described above and published studies (Boulday
et al., 2009; Whitehead et al., 2009) establish that HEG,
CCM2, and CCM2L all function in endothelial cells during
cardiovascular development. The observations that (1)
CCM2L competes with CCM2 for CCM1 binding but does not
bind CCM3, (2) Ccm2L is expressed in a dynamic manner in
endothelial cells, and (3) Heg/;Ccm2L/ embryos exhibit
a cardiovascular phenotype distinct from that of Ccm2/
and Heg/;Ccm2+/ embryos suggested either that CCM2L
and CCM2 operate in discrete endothelial signaling path-
ways downstream of HEG or that these two pathways may(O–T) Ccm2LGFP is expressed in the endothelial cells of nascent vessels. Ccm2LG
vessels (O), such as those that invade the neural tube (nt) at E10.5–E11.5 (P an
neonatal retina (S and T). Scale bars indicate 20 mm unless otherwise indicated.
See also Figure S1 and Table S1.
Developcompete with each other in a dynamic manner determined by
the relative levels of CCM2L and CCM2. To determine if
CCM2 and CCM2L function in discrete or intersecting path-
ways, we next performed genetic experiments to test the rela-
tionship between Ccm2 and Ccm2L during cardiovascular
development.
To test for functional redundancy between CCM2 and
CCM2L, we first generated Ccm2L/;Ccm2+/ compound
mutant animals. Ccm2L/;Ccm2+/ mice were born in normal
numbers and appeared healthy and fertile (data not shown),
suggesting that CCM2 and CCM2L are not redundant in
function. To further address whether CCM2 and CCM2L are
functionally redundant in vivo, we performed complementation
experiments in zebrafish embryos. The cardiac phenotype
conferred by loss of ccm2 in zebrafish embryos can be
efficiently rescued by the injection of wild-type ccm2 cRNA
(>90% rescue) but not by cRNA encoding a ccm2 PTB domain
mutant (Kleaveland et al., 2009). To determine if ccm2L
can compensate for loss of ccm2 in vivo, we coinjected ccm2
or ccm2L cRNAs with ccm2 morpholinos into zebrafish
embryos. cRNA encoding ccm2 but not ccm2L efficiently
rescued the cardiovascular phenotype of ccm2-morphant
embryos (Figures 4A–4E), despite successful expression of
ccm2L protein (data not shown). These studies, and the finding
that CCM2 but not CCM2L can bind CCM3, indicate that CCM2
and CCM2L do not play functionally redundant roles down-
stream of HEG.
Biochemical studies revealed that CCM2L and CCM2
compete for binding to CCM1 (Figures 1F and 1G), suggesting
that expression of CCM2L could reduce CCM2 signaling in
endothelial cells. To determine if CCM2L might modulate
signaling by CCM2, we next tested the effect of changes in the
balance of Ccm2 and Ccm2L gene dosage on cardiovascular
development by examining the effect of loss of a Ccm2 allele
on Heg-Ccm2L compound mutants and vice versa. Although
allHeg/;Ccm2L/ embryos and allHeg/;Ccm2+/ embryos
died prior to E12 because of defects in heart and branchial
arch artery development, respectively, approximately half of
Heg/;Ccm2L/;Ccm2+/ animals generated by Heg+/;
Ccm2L/ 3 Heg+/;Ccm2L/;Ccm2+/ matings survived
(Figures 4F–4L, p < 0.05). Matings between Heg+/;
Ccm2L/;Ccm2+/ animals and surviving Heg/;Ccm2L/;
Ccm2+/ animals confirmed that all Heg/;Ccm2L/;Ccm2+/+
offspring died in utero, whereas half of Heg/;Ccm2L/;
Ccm2+/ offspring exhibited normal cardiovascular develop-
ment (Figures 4F–4K; Table S3, p < 0.01). Finally, intercrosses
of surviving Heg/;Ccm2L/;Ccm2+/ animals revealed that
all liveborn offspring were Heg/;Ccm2L/;Ccm2+/, whereas
all Heg/;Ccm2L/;Ccm2+/+ and all Heg/;Ccm2L/;
Ccm2/ embryos died in utero (data not shown, p < 0.01).
Thus, the survival of Heg/;Ccm2L/;Ccm2+/ animals is an
effect of Ccm2 versus Ccm2L gene dosage and not selection
for a favorable background strain. Finally, to further test whetherFP was frequently detected in nonlumenized endothelial extensions of existing
d Q), and microvasculature (R), and in newly formed microvasculature of the
mental Cell 23, 342–355, August 14, 2012 ª2012 Elsevier Inc. 347
10
Ve
lo
ci
ty
 (c
m/
s)
0
-10
0                                 1000 Time (ms)
0
20
40
60
 
 
 
Fr
ac
tio
na
l
Sh
or
te
ni
ng
 (%
)
*
0
10
20
30
40
50
 
Br
D
U+
 C
el
ls
in
 V
e
n
tri
cl
e 
(%
)
Total EC MC
*
*
A DB E
C
0
-10
10
Ve
lo
ci
ty
 (c
m/
s)
0                                 1000   Time (ms)
F
L
G H I
G’ H’ I’
M
BAA BAA
Ccm2L  Heg-/--/-
Ccm2L-/-
Ccm2L-/-
Ccm2L   Heg-/--/-Cc
m2
L-
/-
Cc
m2
L  
 
He
g-/
-
-
/-
Ccm2L-/-
Ccm2L  Heg-/--/- Ccm2L  Hegfl/--/- Ccm2L  Hegfl/--/-
Tie2Cre+
0
0.25
0.50
0.75
1.00
1.25
CC
M
2L
-/-
:C
CM
2L
+/
+
 
 
 
H
ea
rt 
Ex
pr
es
sio
n
Nr
g1 Fg
f9
Fg
f12
Fg
f16
N
0
0.50
1.00
1.50
 
 
H
ea
rt 
Ex
pr
es
sio
n 
as
fo
ld
 o
f C
CM
2L
+/
-H
eg
+/
-
Nrg1 Fgf9 Fgf12 Fgf16
O
0
5
10
15
20
25
 
 
Ad
-C
cm
2L
:A
d-
-L
ac
Z
Ex
pr
es
sio
n 
in
H
M
VE
Cs
Fg
f9
Fg
f12
Fg
f16
P
Ccm2L   Heg+/-+/-
Ccm2L   Heg+/--/-
Ccm2L   Heg-/-+/-
Ccm2L   Heg-/--/-
1.14
0.79
0.44
0.30
1.11
19.95
4.68
J
J’
K
K’
*
P<0.01
*
*
*
*
Figure 3. HEG-CCM2L Signaling Is Required for Endocardial Growth Factor Expression during Cardiac Development
(A–F) Ccm2L/; Heg/ embryos exhibit patent branchial arch arteries and normal blood circulation. E9.5 Ccm2L/ and Ccm2L/; Heg/ embryos
are shown. Blood can be visualized in the great vessels (A and D) and patent branchial arch arteries (BAAs) demonstrated by hematoxylin and eosin
(H&E) staining of transverse sections (B and E). Doppler ultrasound was used to detect normal systolic flow in the aorta of Ccm2L/; Heg/ embryos
(C and F).
(G–I) Ccm2L/;Heg/ embryos exhibit cardiac thinning, reduced trabeculation, and heart failure after E10.5. H&E stained transverse sections of E10.5
Ccm2L/ and Ccm2L/; Heg/ embryos are shown, with magnification of the boxed regions below. In addition to marked thinning of the heart wall (arrows,
H’ and I’) and reduced ventricular trabeculation, Ccm2L/; Heg/ embryos develop dilated atria, a sign of cardiac failure.
(J and K) HEG-CCM2 signaling is required in the endocardium for myocardial growth. H&E stained transverse sections of E10.5 Ccm2L/;Hegfl/ and
Ccm2L/;Tie2-Cre;Hegfl/ embryos are shown, with magnification of the boxed regions below (J’ and K’).
(L) Ccm2L/;Heg/ embryo hearts exhibit reduced systolic function. Fractional shortening of littermate embryo hearts was measured in utero at E10.5 with
high-frequency ultrasound. n = 4.
(M) Ccm2L/; Heg/ embryo hearts have reduced BrdU uptake in myocardial, but not endocardial, cells at E10.5. n = 3. Scale bars indicate 50 mm.
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Figure 4. Ccm2 and Ccm2L Play Opposing
Rather than Redundant Roles during
Cardiovascular Development
(A–E) ccm2L does not rescue loss of ccm2 in
zebrafish embryos in vivo. Zebrafish embryos
were injected with control morpholino alone (A),
morpholino directed against ccm2 alone (B), or
with ccm2 cRNA (C) or with ccm2L cRNA (D), and
the presence of a dilated heart (red circle) pheno-
type scored 48 hpf. ccm2 cRNA conferred highly
efficient (>90%) rescue of the ccm2 morphant
phenotype, but ccm2L cRNA did not (E). n = 6;
error bars indicate SEM.
(F–K) Loss of Ccm2L rescues loss of Ccm2 during
cardiovascular development. E9.5 embryos lack-
ing different numbers of Ccm2 and Ccm2L alleles
were generated on a Heg/ background to test
for genetic interaction. Loss ofCcm2L rescued the
defect in branchial arch artery (BAA) lumenization
and embryonic lethality observed with loss of
Ccm2 (I–K). White scale bars indicate 500 mm;
black scale bars indicate 100 mm.
(L) The ratio of observed/expected offspring
of Ccm2L/Heg+/ 3 Ccm2L/Heg+/Ccm2+/
matings at P14 is shown.
(M) The ratio of observed/expected offspring of
Tie2-Cre;Ccm2L/Heg+/ 3 Ccm2L/Hegfl/fl
Ccm2fl/fl matings at P14 is shown. Red lettering
and arrows indicate combinatorial lethality; green
lettering and arrows indicate combinatorial rescue
of lethality.
See also Figure S3 and Table S3.
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CCM2L Controls Vascular Stability and GrowthHEG, CCM2, and CCM2L interact specifically in endothelial
cells, we crossed Tie2-Cre;Heg+/;Ccm2L/ and Hegfl/fl;
Ccm2L/;Ccm2fl/fl animals (Figure S3). Although all Tie2-Cre;
Hegfl/;Ccm2L/ animals died before E11 because of cardiac
failure (Figures 3K and 4L), liveborn Tie2-Cre;Hegfl/;Ccm2L/;
Ccm2fl/+ animals were observed, demonstrating rescue with
endothelial-specific loss of CCM2 (Figure 4M). These genetic
studies identify an endothelial cell autonomous signaling
pathway and reveal that loss of CCM2L can compensate for
loss of CCM2 during development and vice versa. CCM2L and
CCM2 therefore play roles in opposing pathways downstream
of HEG in endothelial cells in vivo, and an appropriate balance
of CCM2 andCCM2L expression is critical at multiple time points
during cardiovascular development.
CCM2L Inhibits Endothelial Lumen Formation
and Loosens Endothelial Cell Junctions In Vitro
Endothelial loss of CCM2 prevents lumen formation in collagen
gels in vitro and results in a nonlumenized branchial arch artery(N) Ccm2L/ embryo hearts exhibit reduced Fgf12 and Fgf16 mRNA expressio
qPCR and represented as the ratio of Ccm2L/:Ccm2L+/+ expression. n = 5 for
(O) Ccm2L/; Heg/ embryo hearts exhibit severely reduced levels of Fgf16 mR
and represented as the ratio of the indicated genotypes to Ccm2L+/; Heg+/ ex
(P) CCM2L drives expression of FGF12 and FGF16 in cultured endothelial cells
encoding Ccm2L or LacZ and the indicated mRNAs measured using qPCR after 4
(L–P) indicate SEM.
See also Figure S2 and Table S2.
Developin vivo (Kleaveland et al., 2009; Whitehead et al., 2009). The
observation that loss of CCM2L can rescue branchial arch artery
lumenization in Heg/;Ccm2+/ embryos suggested that
CCM2L may also oppose the known role of CCM2 in lumen
formation. Ccm2LGFP expression is only detected in the endo-
thelial cells of growing cardiovascular organs in vivo, and
Ccm2L expression in cultured endothelial cells was also
extremely lowwhenmeasured by RT-PCR (Figure S4). We there-
fore used adenoviral vectors to express CCM2L or the control
proteins b-galactosidase (LacZ) or GFP in cultured endothelial
cells. Expression of CCM2L, but not LacZ or GFP, significantly
inhibited lumen formation by cultured HUVECs (Figures 5A and
5B; Movie S1). Conversely, siRNA directed against CCM2L
(Figure S4) conferred an increase in endothelial lumen formation
(Figures 5C and 5D).
In vivo and in vitro studies have established that HEG-CCM2
signaling also positively regulates endothelial cell junctions,
in part by reducing RHO activity and expression level (Borikova
et al., 2010; Glading et al., 2007; Kleaveland et al., 2009;n at E9.5. mRNA levels of the indicated growth factors were measured using
each genotype.
NA. mRNA levels of the indicated growth factors were measured using qPCR
pression. n = 4 for each genotype.
. Human microvascular endothelial cells were exposed to adenoviral vectors
8 hr. n = 3 for FGF9; n = 10 for both FGF12 and FGF16. *p < 0.01. Error bars in
mental Cell 23, 342–355, August 14, 2012 ª2012 Elsevier Inc. 349
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Figure 5. CCM2L Opposes CCM2 in the
Regulation of Lumen Formation and Endo-
thelial Junctions
(A and B) Expression of CCM2L inhibits endothelial
lumen formation in vitro. Adenoviral vectors were
used to express CCM2L or the control proteins
GFP or LacZ in human umbilical vein endothelial
cells (HUVECs) and lumen formation measured in
a 3D collagen gel. Shown are images of endothelial
cells in representative collagen gels at the indi-
cated time points (A) and the percentage of lumen
area relative to control vector-treated cells (B).
n = 20 collagen gels for the adeno-GFP controlled
experiment and n = 10 for the adeno-CCM2L
experiment. Scale bar is 50 mM. Arrowheads indi-
cate developing multicellular lumens, and arrows
indicate the final border of the lumen structure.
(C and D) Loss of CCM2L accelerates endothelial
lumen formation in vitro. HUVEC lumen formation
was measured following treatment with siRNA
directed against CCM2L or control siRNA. Shown
are images of endothelial cells in representative
collagen gels at 24 hr (C) and the percentage of
lumen area relative to control vector-treated cells
(D). n = 40 collagen gels analyzed for each group.
Arrows indicate lumenized structures.
(E) CCM2L expression reduces microvascular
endothelial cell trans-endothelial electrical resis-
tance (TEER). Microvascular endothelial cells were
treated with adenovirus to express the control
protein b-galactosidase (LacZ) or FLAG-CCM2L
and TEERmeasured on confluent cell monolayers.
n = 4. Asterisk indicates p < 0.01.
(F) CCM2L expression increases the levels of
RHO-A activation and total protein. Shown are
representative immunoblots to detect RHOA-GTP,
RHOA, FLAG-CCM2L, and ACTIN in the micro-
vascular endothelial cell lysate after exposure to
adeno-b-galactosidase and adeno-CCM2L. n = 5
for total RHOA, n = 2 for RHOA-GTP.
(G) CCM2L expression raises the levels of RHOA
but not RAC1 or CDC42 mRNA as detected by
qPCR. n = 5. Asterisk indicates p < 0.01.
(H) Loss of CCM2L does not significantly alter the
level of RHOA activation or protein expression in
microvascular endothelial cells. The blot shown is
representative of two independent experiments.
(I) Loss of CCM2L does not significantly alter expression of RHOA, RAC1, or CDC42 in microvascular endothelial cells. mRNA levels were detected
using RT-qPCR. n = 4; error bars in (B), (D), (E), (G), and (I) indicate SEM.
See also Figure S4.
Developmental Cell
CCM2L Controls Vascular Stability and GrowthWhitehead et al., 2009; Zheng et al., 2010). Expression of
CCM2L significantly reduced transendothelial resistance
(TEER, a measure of endothelial junction tightness) (Figure 5E),
an effect similar to that previously observed with loss of CCM2
or CCM3 (Whitehead et al., 2009; Zheng et al., 2010). Forced
expression of CCM2L also raised the levels of both activated
RHOA (RHOA-GTP), total RHOA protein and RHOA, but not
RAC1 or CDC42, transcripts in microvascular endothelial cells
(Figures 5F and 5G). Reduction of the low basal level of
CCM2L levels in these cells did not significantly alter the level
of activated or total RHOA protein or RHOA mRNA (Figures 5H
and 5I). These findings demonstrate that CCM2L and CCM2
have opposing effects in endothelial cells in vitro as well as
in vivo.350 Developmental Cell 23, 342–355, August 14, 2012 ª2012 ElsevieLoss of CCM2L Retards Tumor Growth and Wound
Healing
The studies described above suggested that CCM2L may play
an important role in promoting vascular growth despite the fact
that it is not required during cardiovascular development. To
further test a potential angiogenic role for CCM2L, we next
examined tumor growth and wound healing, processes known
to require robust vessel growth (Conway et al., 2001; Lyden
et al., 2001). To test tumor growth, 4 3 105 Lewis Lung Carci-
noma (LLC) cells were injected into the flank of Ccm2L/ mice
and littermate controls. LLC tumor growth was markedly
impaired in Ccm2L/ mice relative to wild-type littermates,
and tumors grown in Ccm2L/ animals appeared pale in
comparison with those in control animals (Figures 6A–6C).r Inc.
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Figure 6. CCM2L Is Required for Rapid
Tumor Growth and Wound Healing In Vivo
(A–C) Growth of Lewis Lung Carcinoma (LLC) cells
is severely retarded in CCM2L-deficient mice.
Four hundred thousand LLC cells were injected
into the flank of mature mice and tumor volume
measured at the indicated times after injection.
Tumor weight was measured after harvest at
15 days. n = 10. Representative tumors are shown.
Note the small size and lack of vascularity in
tumors harvested from Ccm2L/ animals.
(D) Ccm2L/ mice are protected from death after
tail vein injection of LLC cells. Survival curves
following tail vein injection of 5 3 105 LLC cells
are shown.
(E and F) Growth of Lewis Lung Carcinoma (LLC)
cells is inhibited in irradiated Ccm2L/ mice re-
constituted with wild-type bone morrow (E, n = 10)
but not irradiated wild-type mice reconstituted
with Ccm2L/ bone morrow (F, n = 12).
(G) Wound healing is retarded in Ccm2L/ mice.
Eight millimeter full thickness wounds were made
in wild-type and Ccm2L/ animals and the
percentage of the original wounded area calcu-
lated at the indicated time points after wounding.
n = 8; error bars in (A), (B), (E), (F), and (G)
indicate SEM.
Developmental Cell
CCM2L Controls Vascular Stability and GrowthCcm2L/ mice were also protected from lethality because of
pulmonary metastases following tail vein injection of 5 3 105
LLC cells (Figure 6D). These findings suggested that endothelial
CCM2L is required for optimal tumor angiogenesis, but
Ccm2LGFP expression could not be detected in the tumors of
Ccm2L+/ animals. To further address the source of CCM2L,
LLC cells were injected into lethally irradiatedCcm2L/ animals
that were reconstituted with wild-type bone marrow (Figure 6E)
and wild-type mice reconstituted with Ccm2L/ bone marrow
(Figure 6F). These studies demonstrated a requirement for
CCM2L in nonhematopoietic cells, consistent with low level
expression of CCM2L in the endothelium of tumor vessels. To
test the role of CCM2L in a more physiologic angiogenic
process, we compared wound healing following full thickness
skin punch biopsy in Ccm2L/ mice and wild-type littermates.
Wound healing was significantly delayed in Ccm2L/ mice
relative to controls (Figure 6E). These findings suggest thatDevelopmental Cell 23, 342–355although CCM2L facilitates rapid angio-
genic responses in postnatal animals.
DISCUSSION
CCM2L Promotes Vascular
Remodeling by Blocking Canonical
CCM Signals
Diseases such as ischemia and cancer
are characterized by inadequate or
excessive vascular growth. In the former,
vessels remain excessively stable and fail
to sprout new vessels to feed blood-
starved tissues. In the latter, there is
excess vascular permeability and newvessel formation that fuels tumor growth and inflammation.
Understanding the molecular signals that balance vascular
stability and growth is essential to devise effective angiogenic
therapies. The CCM pathway has recently been identified as
a positive regulator of endothelial cell junctions and vessel
stability in both developing and mature animals (Kleaveland
et al., 2009; Stockton et al., 2010; Whitehead et al., 2009).
Ccm2 is expressed at low levels in endothelial cells, and
increased permeability in Ccm2+/ mice (Stockton et al., 2010)
is consistent with a role for CCM2 in generating tonic stabilizing
signals in the cardiovascular system. In the present study we
identify CCM2L as an endothelial-specific modulator of CCM
signaling that is linked to cardiovascular growth. Our studies
suggest that CCM2L both opposes CCM2-mediated endothelial
and vascular stability and activates endothelial growth factor
expression in the heart. These findings are consistent with
a model in which dynamic expression of CCM2L functions as, August 14, 2012 ª2012 Elsevier Inc. 351
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Figure 7. Model of CCM2L Function during
Cardiovascular Growth
(A) In the absence of CCM2L, constitutive
expression of CCM2 confers tonic positive regu-
lation of endothelial junctions and vessel stability.
(B) In response to as yet unidentified angiogenic
signals, CCM2L is expressed in a restricted
number of endothelial cells in actively growing
cardiovascular organs. CCM2L competes with
CCM2 for CCM1 and uncouples CCM1 from
CCM3 to break the tonic CCM signal. In the
absence of CCM2-CCM3 signaling, CCM2L-
expressing endothelial cells are able to uncouple
from neighboring endothelial cells in preparation
for cellular proliferation and migration.
(C) HEG-CCM2L signaling in the developing heart
drives endocardial expression of growth factors
and myocardial proliferation.
Developmental Cell
CCM2L Controls Vascular Stability and Growtha molecular means of converting a tightly connected, quiescent
endothelial cell to a one that is disconnected and actively
participating in vessel or cardiac growth (Figure 7). CCM2L upre-
gulation therefore provides a simple and elegant molecular
mechanism by which stabilizing signals are turned off and
growth signals turned on in a coordinated manner via changes
in a single endothelial cell pathway.
Tight Regulation of CCM2L Expression Reflects Its Role
in Balancing Vessel Stability versus Growth through the
CCM Pathway
Comparison of CCM2L expression with that of CCM2 reveals
important differences and similarities. Studies of Ccm2LacZ
animals reveal broad Ccm2 expression in vivo with no detect-
able vascular pattern or dynamic changes in gene expression
level (Kleaveland et al., 2009). In contrast to Ccm2, studies of
Ccm2LGFP animals reveal tight precise spatial and temporal
control of Ccm2L expression in vivo. Spatially, Ccm2LGFP is
entirely restricted to endothelial cells, consistent with a highly
specific role in regulating cardiovascular CCM signaling.
Temporally, Ccm2LGFP expression is very dynamic and highest
during peak cardiac and vessel growth (e.g., in the E11 heart
and neonatal retina). Like both Ccm1 and Ccm2, however,
Ccm2L expression is undetectable in a majority of endothelial
cells in vivo, even when deficient animals exhibit significant
cardiovascular phenotypes, such as defects in tumor angio-352 Developmental Cell 23, 342–355, August 14, 2012 ª2012 Elsevier Inc.genesis and wound healing. Our bio-
chemical, cellular, and genetic studies
suggest that a primary role of CCM2L
is to oppose CCM2 by competing for
binding to CCM1 and thereby dynami-
cally regulate CCM signaling. Dynamic
modulation of CCM signaling using this
mechanism is only possible if the relative
levels of these three proteins is in a
similar range so that endothelial cells
can transition rapidly between stable,
nonangiogenic states and unstable,
angiogenic states by altering CCM2L
expression. Consistent with such amechanism, we detected similar levels of mRNA transcripts
encoding CCM2L and other CCM proteins in cultured endothe-
lial cells (Figure 2F). Although CCM2L may also affect CCM
signaling through an as yet unidentified indirect mechanism,
these studies support a model in which endothelial CCM
signaling is mediated by low levels of CCM1, CCM2, and
CCM2L that are tightly balanced by expression of CCM2L to
regulate endothelial cell stability versus growth in the func-
tioning vascular network.
The Role of CCM2L in Angiogenesis May Be to Enable
but Not Stimulate Endothelial Proliferation
The in vivo phenotypes of CCM2L-deficient mice support
a role for CCM2L in angiogenesis. Most of the angiogenic
regulators identified to date that act on or within endothelial
cells have been shown to regulate endothelial proliferation.
Despite a correlation with active angiogenic states, however,
GFP+ endothelial cells in Ccm2LGFP animals are not more
BrdU+ than GFP endothelial cells, we do not detect high
Ccm2LGFP expression in retinal tip cells, and Ccm2L levels in
cultured endothelial cells are not increased by VEGF (Fig-
ure S4B). Instead, our biochemical, cellular, and genetic
studies support a specific role for CCM2L in opposing the
stabilizing signals mediated by CCM2 and CCM3. These find-
ings are consistent with a model in which CCM2L enables
endothelial cells to respond effectively to growth factors such
Developmental Cell
CCM2L Controls Vascular Stability and Growthas VEGF by releasing them from neighboring cells, but is not
a proliferative signal itself. For example, in the retina tip cells
arise by active competition among stalk cells for VEGF
signaling (Jakobsson et al., 2010). By the time an endothelial
cell assumes a tip cell position, it has already responded to
VEGF signals and has been released from the constraint of
other endothelial cells and perhaps downregulated Ccm2L
expression.CCM2L Couples CCM Signaling to Cardiac Growth
Our studies identify two lethal loss of function phenotypes,
defective branchial arch artery formation in E9 Heg/;
Ccm2+/ embryos and inadequate cardiac growth in E10.5
Heg/;Ccm2L/ embryos, that can be reversed by further
loss of either CCM2L or CCM2 to restore the balance of these
two proteins. Defective branchial arch artery formation in
Ccm2/ and Heg/;Ccm2+/ embryos occurs when endothe-
lial cells align correctly along the branchial arch but fail to asso-
ciate into a lumenized vessel that connects the heart to the
dorsal aorta (Boulday et al., 2009; Kleaveland et al., 2009; White-
head et al., 2009). This in vivo phenotype strongly resembles the
failure of CCM2-deficient endothelial cells to lumenize in
collagen gels in vitro (Whitehead et al., 2009) and is consistent
with the known role for CCM signaling in regulating endothelial
cell-cell association and lumen formation. In contrast, HEG-
CCM2L signaling is required for cardiac trabeculation and
myocardial growth at E10–E11 (Figure 3), and expression
studies of embryonic hearts lacking one or both of these
proteins as well as endothelial cells that overexpress CCM2L
support reduced endothelial expression of essential myocardial
growth factors, such as FGF16 (Lu et al., 2008), as the mecha-
nism for this phenotype. One possible explanation for the drop
in endocardial growth factor expression in these animals is
a failure of endocardial cells to disengage and expand because
of inadequate suppression of CCM2 signaling, but endocardial
proliferation is not reduced in these hearts (Figure 3M). These
findings therefore suggest that HEG-CCM2L signaling supports
cardiac growth through regulation of endothelial growth factor
expression. The observation that cardiac lethality in Heg/;
Ccm2+/ embryos can be reversed by loss of one Ccm2 allele
is consistent with bidirectional competition and a mechanism
by which myocardial growth is coupled to endocardial growth
in the developing embryo. Further studies to test the role of
HEG-CCM2L signaling and identify the downstream effectors
by which it controls the expression of endocardial growth
factors are an important next step in these studies.EXPERIMENTAL PROCEDURES
Mice
The Ccm2L gene was disrupted in SV129 ES cells by replacing the coding
portion of exon 1, intron 1, and exon 2 with a cassette expressing nuclear-
GFP using recombineering-based gene-targeting techniques. HEG-deficient
and CCM2-deficient mice have been described previously (Kleaveland et al.,
2009). The conditional Heg allele was generated using gene-targeting as
described in Figure S2. The conditional Ccm2 allele was generated using
gene-targeting as described in Figure S3. Tie2-Cre transgenic mice were
obtained from Jackson Research Laboratories (Bar Harbor, ME, USA). The
University of Pennsylvania Institutional Animal Care and Use Committee
approved all animal protocols.DevelopHistology
Embryos at desired developmental stages were dissected and analyzed as
previously described (Kleaveland et al., 2009). The primers used to generate
a Ccm2L in situ hybridization probe are listed in the Supplemental Experi-
mental Procedures. The following antibodies were used for immunostaings:
goat anti-GFP (1:100, Abcam, Cambridge, UK), rat anti-Flk1 (1:50, BD Phar-
Mingen, Franklin Lakes, NJ, USA), rat anti-Pecam (1:500, BD PharMingen),
and mouse anti-BrDU (1:10, Hybridoma Bank, Iowa City, IA, USA).
In Vivo BrDU Incorporation Assay
Pregnant mice were injected intraperitoneally with 100 mg/g body weight
BrDU. The embryos were dissected 1.5 hr after the injection, fixed, and
embedded in paraffin. Paraffin sections were immunostained with anti-BrDU
and anti-PECAM antibodies and nuclei visualized with DAPI.
Tumor Xenograft, Bone Marrow Transplant, and Wound Healing
Studies
Three-month-old Ccm2L/ and littermate control mice were injected with
43 105 Lewis Lung Carcinoma (LLC) cells subcutaneously on the flank. Start-
ing one week after injection, tumor size wasmeasured every two days. Tumors
were excised andweighed 15 days after injection. For radiation chimera exper-
iments bonemarrow was isolated fromCcm2L/ or control littermate animals
and transplanted by retro-orbital injection into recipient Ccm2L/ or control
littermate animals conditioned with a split lethal dose of 10 Gy irradation.
LLC cells were injected subcutaneously 8 weeks after transplantation. To
test the survival following lung metastasis, 3-month-old Ccm2L/ and litter-
mate control mice were injected with 53 105 LLC cells via tail vein and survival
monitored daily. Full thickness wounds were made on the dorsum of 3-month-
old Ccm2L/ and littermate control mice using an 8-mm-skin biopsy punch.
Wound dimensions were measured every other day and the wound area
calculated.
Fetal Ultrasound
Pregnant mice were lightly anesthetized with 1%–2% isoflurane and
trans-uterine embryonic ultrasound performed as previously described (Lee
et al., 2006). Left ventricular systolic function was estimated by the percent
change in fractional area (FAC%), which was derived using the formula:
(Vd-versus) / Vd 3 100. Doppler ultrasound was used to detect blood flow in
the dorsal aorta.
Zebrafish Studies
Tuebingen long-fin wild-type zebrafish were maintained with approval of the
Institutional Animal Care andUse Committee of the University of Pennsylvania.
Antisense morpholino oligonucleotides (Gene Tools) that interfere with the
splicing of ccm2 (Mably et al., 2003, 2006) were injected into the yolk of
one-cell stage embryos at a dose of 5 ng. To rescue the phenotype conferred
by ccm2 morpholinos, 100 pg of cRNA encoding ccm2 or ccm2L was coin-
jected with the ccm2 morpholino oligonucleotides.
Measurement of Trans-Endothelial Electrical Resistance
Human dermal microvascular endothelial cell (HMEC) barrier function was
assayed by measuring the resistance of a cell-covered electrode using an
ECIS instrument (Applied BioPhysic, Troy, NY, USA) as previously described
(Zheng et al., 2010). Cells were infected with adenovirus expressing b-galac-
tosidase or CCM2L at 5,000 gc/cell. TEER was measured 72 hr after infection.
Endothelial Lumen Formation
Endothelial cell lumen formation assays were performed in three-dimensional
(3D) collagen matrices, real-time movies acquired, and cultures fixed and
quantitated for lumen formation as described as described (Koh et al., 2008).
Immunoprecipitation, Immunoblotting, and RHO Activation Assays
Biochemical studies of epitope-tagged proteins heterologously expressed in
HEK293T cells were performed as previously described (Kleaveland et al.,
2009; Zheng et al., 2010). RHO activation was measured using a RHO Activa-
tion Assay Biochem Kit (Cytoskeleton, Denver, CO, USA). Anti-ACTIN staining
(1:5,000; Cell Signaling, Danvers, MA, USA) was used as a loading control.mental Cell 23, 342–355, August 14, 2012 ª2012 Elsevier Inc. 353
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The p values were calculated using an unpaired two-tailed Student’s t test,
ANOVA, or chi-square analysis as indicated.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, three tables, Supplemental
Experimental Procedures, and one movie and can be found with this article
online at http://dx.doi.org/10.1016/j.devcel.2012.06.004.
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